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Summary
Background: The presenting symptoms of coeliac disease are often subtle and the
diagnosis is frequently delayed or overlooked. Therefore, especially elderly patients
may be denied the benefits conferred by gluten free diet which can be dramatically
life-changing.
Aim: To review the occurrence, clinical features, diagnosis and management in coe-
liac patients detected later in life.
Methods: To review manuscripts concerned with coeliac disease in the elderly and
to derive subgroups of elderly people from publications on the disorder.
Results: Approximately a quarter of all diagnoses are now made at the age of
60 years or more and a fifth at 65 years or over. About 4% are diagnosed at
80 years or above. Around 60% remain undetected, since their symptoms are often
subtle: tiredness, indigestion, reduced appetite. Good compliance with gluten free
diet, resolution of symptoms and improvement in laboratory indices can be achieved
in over 90% of patients.
Conclusions: Coeliac disease not uncommonly presents for the first time in older
patients and is an important diagnosis to make.
The Handling Editor for this article was Professor Jonathan Rhodes, and this uncommis-
sioned review was accepted for publication after full peer-review.
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1 | INTRODUCTION
In past decades, coeliac disease was thought to mainly affect chil-
dren and young adults. Today we have learnt that the disorder may
be detected at any age, and is regarded as one of the commonest
chronic disorders encountered worldwide with a serological preva-
lence of about 1%-2%.1,2 The advent of an endoscopic technique to
obtain duodenal biopsies quickly and the development of reliable
serological screening tests have been responsible for this remarkable
turnaround.
In a proportion of older people the symptoms go back to child-
hood but the diagnosis of coeliac disease is not made because they
either do not present to health care workers or the diagnosis is
missed only to be arrived at often many years later.3 Compared to
younger patients, the clinical picture may thus be different when the
disease is diagnosed at advanced age. The diagnostic delay has prob-
ably been longer, and in any case, these individuals will have been
consuming gluten for many decades. This may expose them to long-
term consequences of malabsorption and to complications of coeliac
disease.4 Some might argue why the diagnosis of coeliac disease
should be pursued in the elderly, especially when symptoms are only
mild and adopting a gluten free diet demands considerable changes
in life style. The evidence points to the value of making the diagno-
sis in this population. Mild symptoms do not necessarily equate to a
satisfactory quality of life in elderly people with coeliac disease with-
out gluten free diet.3 The case for pursuing the diagnosis in the
elderly is compelling but patients of course, will make the final deci-
sion about how they wish to proceed. In any event, older people are
increasingly unwilling to put up with ill health that might indicate
coeliac disease and are rightly demanding investigation. Old age
itself should never be blamed for clinical features such as tiredness,
indigestion, reduced appetite or anaemia which may be due to coe-
liac disease.3,5
2 | REVIEW CRITERIA
We searched PubMed, Medline and Cochrane library for articles
published in English until May 2017. We used the terms celiac dis-
ease, coeliac disease, age, ageing, elderly, and dermatitis herpeti-
formis. We utilised such articles where it was possible to distinguish
clinical features, diagnosis or management of coeliac disease later in
life.
3 | PREVALENCE AND INCIDENCE
The overall prevalence of coeliac disease in the elderly is expected
to rise because life expectancy generally is getting longer, and the
mortality rate is not much different from the population in general.6,7
Older people are increasingly unwilling to put up with ill health that
might indicate coeliac disease and are rightly demanding
investigation.
The published prevalence figures of coeliac disease vary widely,
depending on the target population and the study design. Coeliac
disease antibody testing, especially with IgA class endomysial anti-
bodies and tissue transglutaminase antibodies, offers a powerful tool
for screening, and most prevalence studies are therefore based on
this approach8-10.
Epidemiological studies of coeliac disease in elderly people are
sparse. In Finland, the overall prevalence of coeliac disease was
1.99%, and 1.2% in the patients over 75 years of age.1 Casella et al
found that in their cohort comprising 1225 coeliac disease patients,
4.8% were over 65 years of age at the time of examination.11 In a
further series only 4.4% were over the age of 65 years at diagno-
sis.12 Tortora et al13 reported an even lower percentage; in their ser-
ies only 2.5% were detected in individuals over 65 years of age. This
series was collected in a tertiary referral centre and almost certainly
referral bias was responsible for this low result. More realistic figures
come from the coeliac disease clinic in Derby, UK, which is not a
referral centre. Here, 28% and 21% were diagnosed by small intesti-
nal biopsy at the ages of 60 years or more or 65 years and over,
respectively.14 About 4% were diagnosed at or over the age of
80 years. Among the Asian population there is a dearth of diagnoses
in later life. Only 5% of Asians were diagnosed in the Derby clinic at
or over the age of 60 years which is far less than for whites.14 In a
series from New Delhi, only 9% were diagnosed at the age of
50 years or more.15 Whether coeliac disease is uncommon in elderly
Asians or these individuals are not presenting for diagnosis remains
to be determined.
It is possible to derive prevalence data from many publications
focusing on the epidemiology of coeliac disease. Table 1 summarises
such screening studies, where the prevalence figures in the whole
study population and in subgroups of older people can be estimated.
The prevalence figures seem in general to be lower in older series
than in the general population. As the Table shows, the Finnish
study seems to make an exception, reporting a higher prevalence of
coeliac disease in elderly patients.16 These differences may be due
to patient selection; the Finnish study was population-based, and
also included patients already diagnosed on clinical grounds prior to
screening.
The prevalence figures in screening studies must be differenti-
ated from those obtained in clinical practice. Figures for the occur-
rence of diagnosed coeliac disease are much lower than what have
been reported in screening studies. Apart from study population and
design, figures obtained depend on the diagnostic accuracy and the
use of serologic screening in everyday clinics. Vilppula et al17
reported that the frequency of clinically detected coeliac disease in
patients over 50 years of age was 0.89%, while the overall popula-
tion prevalence in same area was 0.5%-0.7% over approximately the
same period.18.
As stated earlier, endomysial antibodies and tissue transglutami-
nase antibodies afford a high specificity for coeliac disease. More-
over, seropositive individuals with normal villous architecture often
develop coeliac disease later in life.19 Therefore, the combined
biopsy-proven and seroprevalence is of interest. The Finnish series
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show that this was as high as 2.7% in individuals over 50 years of
age (Table 1).16.
Like the prevalence data (Table 1), some incidence data in the lit-
erature can be obtained separately for elderly people. The overall
annual incidence figures vary quite markedly (Table 2). This variabil-
ity can be attributed to different diagnostic strategies and efficacy,
and due to the overall diagnostic delay. In adults of all ages, the
annual incidence figures have been inconsistent, but are in general
not lower in older than in younger coeliac patients, as shown in
Figure 1.
Coeliac disease is more common in females than males with an
overall female to male ration of 2:1 in white populations.2,14,20 How-
ever, there was a paucity of diagnoses in young men < 20 years of
age giving a ratio of 4:1. This difference in gender diminished in later
years. For those aged 60 years or over at diagnosis, the female male
ratio was found to be 1.4:1.14 What could help to explain these gen-
der differences? Women are more likely to develop autoimmune dis-
orders than men21 and women use health-care facilities more than
men so are more likely to be diagnosed with coeliac disease. Women
are more symptomatic than men22 and this may lead to earlier diag-
nosis and men may delay presenting to healthcare professionals.23
An interplay between sex hormones and the gastrointestinal micro-
biota may prevent men from developing coeliac disease. In rodents,
it has been shown that this interplay increases the prevalence of
autoimmunity in females.24 Increasing age might reduce this inter-
play as sex hormone levels decrease.
To conclude, coeliac disease, including undetected, is common in
the elderly, the disorder may manifest at any age, seropositive indi-
viduals may later develop coeliac disease regardless of their age, and
seropositivity may appear also later in life.16
4 | CLINICAL MANIFESTATIONS
4.1 | Symptoms and malabsorption
Classic symptoms of coeliac disease are weight loss, diarrhoea, and
fatty stools indicative of malabsorption. When these are present
making the diagnosis of coeliac disease is relatively straight forward
although it can still be overlooked. However, most patients now pre-
sent with non-classical features such as fatigue; dyspepsia; vague
abdominal pain suggestive of irritable bowel syndrome;25 constipa-
tion; and characteristics such as poor growth, anaemia, mouth ulcers,
osteoporosis and neuropathy. This clinical diversity often delays or
obscures the diagnosis of coeliac disease and particularly so in the
elderly when it is easy to dismiss such symptoms as due to “old age”
and of no real consequence. This was illustrated by a series reported
by Hankey and Holmes3 who found a delay of 28 years in those
diagnosed at the age of 60 years or over; the maximum delay was
TABLE 1 The prevalence of coeliac disease; the figures in different age groups have been derived from the Results of the original
publication
Study, year Country Population
Screening
method
n total
n subpopulation
Population age
subpopulation
age (y)
Biopsy-proven
prevalence (%)
Sero-prevalence
(%)
Kolho et al, 199881 Finland Voluntary personnel EMA 1070 18-65 0.77 1.03
58-65 0.09 0.18
Ivarsson et al, 199982 Sweden General population AGA, EMA 1894 25-74 0.53 0.32
57-68 0.37
Volta et al, 200183 Italy General population EMA 3483 12-65 0.49 0.57
632 56-65 0.32
West et al, 20032 UK Health survey EMA 7527 45-76 — 1.2
4696 55-76 1.0
Catassi et al, 200776 USA Primary care at-risk
patients
TTGA,EMA 976 ≥18 — 3.07
366 ≥60 1.37
Lohi et al, 20071 Finland Heath survey, population
based
TTGA, EMA 8028 ≥30 0.52 2.02
1095 55-64 1.68
812 65-74 1.21
747 ≥75
Vilppula et al, 200916 Finland General population TTGA, EMA 2815 ≥55 2.34 2.70
Godfrey et al, 201037 USA Monoclonal gammopathy
study
TTGA, EMA 16847 ≥50 0.2 0.8
Katz et al, 201184 USA Volunteer health care
participants
TTGA, EMA 3850 ≥18 — 0.8
2727 ≥50 0.7
Almeida et al, 201385 Brazil Unselected out-patients TTGA, EMA 946 ≥60 0.1
EMA, endomysial antibodies; AGA, gliadin antibodies; TTGA, tissue transglutaminase antibodies.
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an astonishing 50 years. It has to be conceded that this was in an
era when awareness of coeliac disease was not as prominent as it is
now. In a more recent cohort of elderly patients,26 the duration of
symptoms was 6.14  12.6 years, similar to that in young adults at
5.8  12 years but unacceptably long delays still occur. Even in
those presenting with classical manifestations, a diagnostic delay of
17 years can occur.12
In the study of Vivas et al,27 typical symptoms were present in
62.5% children vs 31% in adults (P = 0.01). The average time to
diagnosis after the appearance of symptoms was 7.6 months for
children and 90 months for adults (P < 0.001).
Tortora et al13 found no differences in the malabsorption values
between young and elderly people. However, elderly coeliac patients
were more likely than younger ones to be diagnosed due to malab-
sorption symptoms, whereas nonclassic symptoms were less com-
mon in the elderly. This suggests that elderly coeliac patients with
subtle or atypical symptoms may go undetected by the health care
staff.
Table 3 summarises some reports on symptoms or malabsorption
in elderly people with coeliac disease. It is noteworthy that many
patients had not suffered from any obvious symptoms.
4.2 | Dermatitis herpetiformis
Dermatitis herpetiformis is the classic cutaneous manifestation of
extraintestinal coeliac disease. This is a blistering itching skin disease
typically affecting elbows, knees, buttocks and scalp. Granular IgA
deposits of the uninvolved skin are diagnostic. The disease affects
up to 12% of adult coeliac patients.28 In contrast to coeliac disease,
the incidence of dermatitis herpetiformis is decreasing.20,29 It was
suggested that an early diagnosis and treatment of coeliac disease
might lead to less dermatitis herpetiformis.28 The mean age at
TABLE 2 The annual coeliac disease incidence per 100 000 in different age groups; derived from the original publications
Study, year Country Population
Population age
Subpopulation age, (y)
Incidence
All or female/male (%)
Murray et al, 200386 USA Retrospective survey of cases, 1950-2001 Children and adults
≥65
2.1
3.2
Fowell et al, 200687 UK Prospective survey, 1993-2002 Adults
60-74
8.7
16.8
Virta et al, 200918 Finland Database of the National Social Insurance
Institution, 2004-2006
Children and adults 39
55-64 49/36
65-74 53/47
≥75 24/22
Vilppula et al, 200916 Finland General population, 2002-2005 ≥55 75
Godfrey et al, 201016 USA Stored sera, 2001-2011 ≥50 11.8
Angeli et al, 201288 Italy Prospective survey, 2001-2011 in a local
health unit
50-54 92/28
55-59 89/0
60-64 79/56
65-69 40/14
70-74 27/17
75-79 14/20
Ludvigsson et al, 201389 USA Prospective survey, 2000-2010 0-85 17.4
45-64 19.0
65-85 21.7
60.00
50.00
40.00
30.00
20.00
10.00
0.00
Murray (86) Fowell (87)
Whole population Elderly
Virta (18) Ludvigsson (89)
F IGURE 1 The annual incidence of
coeliac disease per 100 000 in the whole
population and in the elderly (65 years or
older in different studies). The respective
references are shown in parentheses.
Population: Murray and Ludvigsson all
ages, Fowell 15 years and Virta 16 years
or older
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diagnosis of dermatitis herpetiformis in our series was 39 years,
which was not much different from that in coeliac disease
(44 years).30 However, dermatitis herpetiformis is fairly uncommon
in children; in our series only 4% of 476 patients were less than
17 years of age.28
B-cell lymphoma in dermatitis herpetiformis may develop more
likely than in those with coeliac disease, who develop typically
enteropathy-associated T-cell lymphoma. In our series, 11 of 1104
patients with dermatitis herpetiformis had non-Hodgkin lymphoma;
eight B-cell lymphoma, two enteropathy-associated T-cell lymphoma,
and one were unclassified. Six of the 11 were over 50 years of age
(median 50, range 32-79 years).31
In general, the clinical course of dermatitis herpetiformis does
not differ between young and elderly patients. A decreased mortality
rate in dermatitis herpetiformis is an intriguing feature. Hervonen
et al32 found the relative risk in mortality to be 0.7; 95% confidence
intervals (CI) 0.55-0.87. A similar trend has been shown in smaller
series, though not statistically significantly.7,33 The risk of lymphoma
in the elderly should be borne in mind, including the B-cell type,
although it may appear in younger people.31
4.3 | Bone mineral density and fractures
Adult coeliac patients have more osteoporosis or osteopenia and
altogether lower bone mineral density than the reference popula-
tion34,35 Osteoporosis, as would be expected, is much more preva-
lent in elderly coeliacs. In one series of patients 65 years or older at
the diagnosis of coeliac disease by biopsy, 67% of males had osteo-
porosis compared with 14% in younger participants, while the corre-
sponding figures for females were 70% and 9%.11 Importantly, it has
been found that reduced bone mineral density can affect those who
have no symptoms of coeliac disease and are discovered by screen-
ing,5,34 or are children who have returned to a normal diet but have
remained symptom free in adult life.35 Meta-analysis showed that
there is a moderate reduction in bone mineral density in untreated
coeliac disease with weighted T-scores at the lumbar spine and hip
of 1.7 and 1.4 (osteopenia defined as T-score 1 to 2.4 an
osteoporosis ≤2.5 standard deviations).36As expected, the same
seems to be true in the elderly, in whom osteopenia and osteoporo-
sis are common.11,37,38
The fracture risk was higher in coeliac disease patients (8.7%)
than in a control population (6.1%) according to a meta-analysis of
Olmos et al39 In another study, a modest increase in risk of fracture
was evident (risk ratio 1.38; 95% CI 1.14-1.68).36 West et al38 in
their population based study reported small increase in fractures in
patients with coeliac disease (hazard ratio 1.30; 95% CI 1.16-1.46)
but considered that undue concern was unwarranted. In some other
small series, the fracture risk was also elevated.5
Osteoporosis can be reliable assessed by measurement of bone
mineral density using non-invasive dual-energy X-ray absorptiometry
(DEXA) but the issue in practice is identifying which coeliac patients
are at most risks of reduced bone mineral density so that investiga-
tions can be rationalised. High risk factors include age over 70 years,
previous osteoporotic fracture, weight loss greater than 10%, and
low body weight.40 A case can therefore be made for limiting DEXA
screening for osteoporosis to new patients with these features, to
those with symptoms despite treatment with a gluten free diet for
1 year and to those who do not adhere strictly to the diet. The frac-
ture risk assessment tool (FRAX) has been devised to limit the need
for DEXA scans.41 The score is based in 10 variables. It appears to
have a high negative predictive value of 94% but further evaluation
of this test is required.
Osteoporosis is just one of many factors predisposing to fracture
and the risk doubles with each standard deviation decrease in bone
mineral density.42 Advice to the elderly about wearing good shoes
and slippers and avoiding hazards that might lead to falls is particu-
larly important to avoid fracture. Apart from dietary advice, this is
especially important for coeliac disease patients.
TABLE 3 Symptoms and signs of malabsorption in older patients with coeliac disease. Derived from the original publications
Reference n Age, y Symptoms Malabsorption
Hankey and- Holmes, UK3 42 >60 45% classic symptoms 80% anaemia (male)
75% anaemia (female)14% subtle symptoms
Freeman et al, Canada90 30 >60 77% weight loss 61% anaemia
40% iron deficiency
37% low vitamin B12
30% low serum folate
Gasbarrini et al, Italy12 60 >65 77% classic symptoms 58% anaemia
3% no symptoms
West et al, UK2 87 45-76 Not described Blood haemoglobin was lower than in control group
Vilppula et al, Finland17 60 >55 31% classic symptoms 50% anaemia or malabsorption
36% subtle symptoms
33% no symptoms
Subtle symptoms, abdominal distention, occasional loose stools or diarrhoea, bloating.
Classic symptoms, chronic diarrhoea, malabsorption (iron, vitamin B12, folic acid), abnormal loss of weight.
COLLIN ET AL. | 567
Among patients with osteoporosis, the prevalence of coeliac dis-
ease has been up to 3.4%;43 only slightly higher than the contempo-
rary knowledge of the frequency of coeliac disease in the general
population. Nevertheless, the possibility of coeliac disease should be
considered in all subjects with osteoporosis or osteopenia, regardless
of their age, since gluten free diet increases bone mineral density
even in asymptomatic coeliac disease patients.34,35
Elevated alkaline phosphatase is a marker of osteomalacia in coe-
liac disease as in the general population. Normalisation of results
with gluten free diet, vitamin D and calcium will remove the need
for further investigation including bone biopsy.4
4.4 | Autoimmune diseases and morbidity
Screening studies have demonstrated an increased prevalence of
autoimmune disorders including type 1 diabetes mellitus, thyroid
disease and liver disorders. Of these diabetes is the best
researched and in about 90% of patients diabetes precedes the
diagnosis of coeliac disease. Apart from diabetes, hypothyroidism
and hyperthyroidism, autoimmune liver disease and primary biliary
cirrhosis deserve special mention. Isolated hypertransaminasemia is
the most common hepatic injury and if this reverses on gluten free
diet no further investigation is required. Primary Sj€ogren’s syn-
drome must be remembered also in elderly coeliac disease
patients.44 These associations have recently been reviewed in
detail.4
In elderly people, the concomitant occurrence of autoimmune
conditions in coeliac disease does not differ from that in adults in
general.13,45 In particular, hypothyroidism is often associated with
coeliac disease in the elderly,17,37 although highest risk estimates for
thyroid disease have been obtained in coeliac children.46 It is uncer-
tain whether gluten free diet can alleviate or prevent the develop-
ment of autoimmune disease, especially in adults.47,48
4.5 | Heart disease and neurological disturbances
Apart from the burden of associated autoimmune diseases in coeliac
patients, an increased risk of ischaemic heart disease has been
reported.49 The overall risk of ischaemic heart disease in coeliac dis-
ease is still debatable, which may be due to differences in smoking
patterns or socioeconomic factors.4 Recent studies have found no
association between gluten intake and the risk of subsequent overall
coronary heart disease.50,51 Nevertheless, gluten free diet may result
in reduced consumption of beneficial whole grains, which may affect
cardiovascular risk, and coeliac patients should be informed about
the potential risks of ischaemic heart disease.51
Various neurological problems have been encountered in coeliac
disease. Many of these associations are still debatable. Patients with
these disturbances should be actively screened serologically for coe-
liac disease. Neuropathy, memory disturbances, ataxia of non-alco-
holic origin and brain atrophy are conditions where coeliac disease
may be associated.52,53 The mean onset of gluten neuropathy and
gluten ataxia occurs at the mean age of 55 years.53,54 It seems that
elderly patients with coeliac disease are overall not at increased risk
for dementia compared to population in general.55 Unfortunately,
neurological conditions are often irreversible in spite of the introduc-
tion of a gluten-free diet.56,57
4.6 | Malignancy and mortality
According to a recent meta-analysis coeliac disease patients, includ-
ing screen-detected cases, were at an increased risk of non-Hodgkin
lymphoma and of all-cause mortality, but not of malignancy in gen-
eral.58 In clinically milder forms, the risk may be lower.6,59 The
increase was due especially to enteropathy-associated T-cell lym-
phoma, and with poor dietary compliance.7,60 Lymphoma in young
coeliac patients is uncommon,11 so the development of malignancy
is mainly a concern in the elderly. In the review by Ludvigsson, the
overall survival of coeliac patients with lymphoproliferative malig-
nancy was the same as that of controls.61
In 2009 Freeman62 stated in his review that when coeliac dis-
ease is diagnosed initially in elderly individuals or late in the clinical
course, the risk of developing lymphoma and other malignancies was
increased. In contrast, Godfrey et al37 observed that in coeliac
patients over 50 years of age there was no significantly greater risk
of cancer or mortality in the undiagnosed coeliac patients than in
the controls.
In contrast to coeliac disease, the risk of B-cell lymphoma was
increased in dermatitis herpetiformis patients. Similar to coeliac dis-
ease patients, the risk was associated with poor compliance to glu-
ten-free diet, but as stated earlier, surprisingly the mortality rate was
decreased in dermatitis herpetiformis.31,63
Refractory coeliac disease is a rare premalignant condition mainly
affecting elderly coeliac disease patients.64,65 The symptoms and
mucosal lesions do not alleviate on a strict gluten free diet. In refrac-
tory coeliac disease type I, the mucosal intraepithelial cell population
is normal, whereas in type II a monoclonal cell population is atypical,
which clearly increases the risk of enteropathy-associated T-cell lym-
phoma.66 Refractory coeliac disease should be managed in special
clinics.67
To conclude, increased risk of lymphoma clusters mainly in
elderly coeliac patients. However, the risk is lower than previously
thought, less than twofold in one recent series compared to that of
the population in general.68 However, the malignant development
should be rigorously investigated in refractory coeliac disease, and in
cases where the patient experiences alarming symptoms or gluten-
free diet is no longer effective.
Recently, Ilus et al68 reported that patients with coeliac disease
carry an increased risk of colon cancer. This has to be borne in mind
in elderly coeliac patients, because this cancer is very common, and
its overall incidence is increasing in the older age groups. In those
with coeliac disease who present with or develop iron deficiency
anaemia, especially in later life, the possibility of concurrent colon
cancer should always be considered. If iron deficiency anaemia is not
reversed by a gluten free diet and supplements, the presence of a
colon cancer should be suspected.
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In the same study,68 the risk of breast cancer in females and lung
cancer were lower than in the population in general; these reduc-
tions may explain why the overall risk of cancer was not increased.68
A similar finding has also been observed non-significantly in smaller
series7
4.7 | How children differ in terms of symptoms
In children, failure to thrive, anaemia and tiredness are typical symp-
toms. Lymphoma and is uncommon, but not absent,69other malig-
nancies occurring in children have not been connected to coeliac
disease. As stated earlier, dermatitis herpetiformis is uncommon.
Also in children, many remain undetected and have subtle if no
symptoms at all.70
4.8 | The effect of gluten-free diet
Adopting a gluten free diet demands considerable changes in life
style. Should the diagnosis of coeliac disease be pursued in the
elderly, especially when symptoms are only mild? Several methods
have been applied to measure quality of life in coeliac disease, these
methods being mainly general and not disease-specific. Studies
focusing on elderly coeliac patients are sparse.
The amelioration of the condition by gluten free diet is obvious
when elderly coeliac patients suffer from classic symptoms or malab-
sorption. The issue becomes more complicated when there are only
subtle, if any, symptoms or signs of malabsorption. Vilppula et al
showed that the diet improves quality of life even in elderly screen
detected coeliac disease patients, also in seemingly asymptomatic
ones.5 This was particularly evident when quality of life was evalu-
ated: in a series of 35 screen detected coeliac patients over 50 years
of, 28 (77%) maintained a strict gluten free diet while five others
ingested gluten less than once per month.5 Compliance seems not to
be a major problem as the majority of elderly coeliac patients, even
apparently asymptomatic ones, adhere to a strict gluten free diet,
which again improved their quality of life. Mucosal recovery is also
expected to be good when the diet is strict,5 although it may occur
more slowly than in younger patients.71 Hankey and Holmes found
that compliance with gluten free diet in the elderly was good: in a
study of 42 patients diagnosed at the age of 60 years or more, 38
(90%) complied strictly with the diet.3 All of these reported a consid-
erable improvement in well-being and resolution of symptoms after
commencing diet. Weight increased by an average of 5.2 kg; blood
haemoglobin, albumin, calcium and alkaline phosphatase levels all
improved significantly to within the normal range after 1 year on
diet.
In the elderly, visual impairment that might impede the reading
of food labels and the reliance on a partner to help with the gluten
free diet. Where possible, partners should be involved in dietary and
management discussions. Elderly patients, especially those who live
alone might easily feel daunted by the thought of changing dietary
habits of a life-time and fearful of the cost implications and how
products might be obtained. For all of these reasons, patients should
be introduced to sympathetic dieticians skilled in the gluten free
diet, so that optimal management can be achieved.72 The risk of
overweight is present after commencing gluten-free diet, and weight
maintenance counselling should be an integral part of coeliac dietary
education.73 Altogether, current limited evidence suggests adherence
to a gluten-free diet and mucosal healing prevents or ameliorates
complications.73
Before the diagnosis is pursued it should be established that
patients are taking a full normal diet, because some will begin elimi-
nating gluten as soon as the diagnosis of coeliac disease is men-
tioned, sometimes on the advice of their physicians. This should be
strongly discouraged as it can make subsequent tests difficult to
interpret.
5 | DIAGNOSTIC WORK-UP OF COELIAC
DISEASE IN ELDERLY PATIENTS
Population-based screening for coeliac disease is not supported by
the current evidence.74 The level of suspicion of coeliac disease
should be as high in older people as in younger ones. Old age itself
should never be blamed for clinical features such as tiredness, indi-
gestion, reduced appetite or anaemia which may be due to coeliac
disease. Individuals found to have coeliac disease through screening
programmes, may have considered themselves as ‘well’ and it is the
physician or healthcare system that is identifying them as potentially
ill. A strategy of case-finding from groups at particular risk is prefer-
able.36 Individuals with a family history of coeliac disease have about
a five-fold risk of having coeliac disease.75 An active case finding
strategy increases the detection of coeliac disease,76 so health care
workers should test patients with suggestive clinical features or
because the belong to an at-risk group, for example, have a family
history or autoimmune diseases, and where necessary, perform small
intestinal biopsy to confirm or refute the diagnosis. Testing for coe-
liac disease in patients with suspected irritable bowel syndrome is
likely to be cost-effective even at a relatively low coeliac disease
prevalence.25
In the series of 40 patients found by serologic screening in the
studies of Vilppula et al,16,17 diagnostic clues were present in almost
every patient’s history, and should alert physicians to consider coe-
liac disease. Patients with clinical features indicative of coeliac dis-
ease may be seronegative, and in these cases obtaining a small
bowel biopsy is mandatory to clarify the situation. Especially elderly
coeliac patients may remain seronegative,77 or tissue transglutami-
nase antibodies titres may be lower than in younger ones.70 In such
symptomatic individuals endoscopic examination will also establish
whether other pathology is present in the upper gastrointestinal
tract. In frail, elderly patients or those with co-morbidities that pre-
clude performing an endoscopy to obtain small bowel biopsies, sero-
logical tests will usually help to establish the diagnosis78,79
There is a role for establishing the HLA-status of patients which
can rule out coeliac disease, as virtually all coeliac patients have
DQ2 or DQ8. However, this is not helpful in the diagnostics of
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coeliac disease, because up to 35% of the population share DQ2 or
DQ8.80
6 | CONCLUSIONS
Coeliac disease is often undetected in elderly people. The lack of
obvious symptoms does not exclude the possibility of the condition.
High index of suspicion and active serological screening in at-risk
groups help to identify elderly patients who evidently benefit from
gluten free diet. The diagnosis may prevent severe complications
such as low-energy bone fractures and enteropathy-associated T-cell
lymphoma.
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